Emergent BioSolutions (EBS) said Monday that the Biomedical Advanced Research and Development Authority executed a contract modification for the second option period, valued at about $16.7 million, for drug product process and analytical testing validation and long-term stability for Ebanga.
Ebanga is indicated for the treatment of infection caused by Zaire Ebola virus.
BARDA is part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services.
The option is part of Emergent's existing 10-year contract with BARDA for advanced development and procurement of Ebanga, with a maximum value of $704 million, the company said.
Shares of Emergent BioSolutions fell past 5% in recent trading.
Price: 9.33, Change: -0.55, Percent Change: -5.57
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。